| Identification | Back Directory | [Name]
Z-360 | [CAS]
209219-38-5 | [Synonyms]
CS-2910
Nastorazepide
Nastorazepide (Z-360)
Nastorazepide Calcium
Z360; Z-360; Z 360; NASTORAZEPIDE.
3-[[[[(3R)-5-Cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2,3,4,5-tetrahydro-2-oxo-1H-1,5-benzodiazepin-3-yl]amino]carbonyl]amino]benzoic acid
Benzoic acid, 3-[[[[(3R)-5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2,3,4,5-tetrahydro-2-oxo-1H-1,5-benzodiazepin-3-yl]amino]carbonyl]amino]- | [Molecular Formula]
C29H36N4O5 | [MDL Number]
MFCD26142609 | [MOL File]
209219-38-5.mol | [Molecular Weight]
520.62 |
| Chemical Properties | Back Directory | [Boiling point ]
742.8±60.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:32.0(Max Conc. mg/mL);61.5(Max Conc. mM) | [form ]
Solid | [pka]
4.16±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Nastorazepide (Z-360), selective, orally available, 1,5-benzodiazepine derivative, is a gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antitumor activity[1]. | [IC 50]
CCKBR | [References]
[1] Kato H, et al. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. Life Sci. 2011 Oct 24;89(17-18):603-8. DOI:10.1016/j.lfs.2011.07.019 |
|
|